With the recent FDA-approval of Provenge^®^ and Yervoy^®^, the field of cancer immunology has gone through a renaissance. A number of therapies including antigen-specific (e.g., vaccination using tumor antigens, adoptive transfer of tumor-infiltrating leukocytes)[@R1] and nonspecific (cytokines, immunostimulatory monoclonal antibodies, TLR antibodies)[@R2] have been attempted both preclinically and clinically with varying degrees of success. While the mechanisms underlying the anticancer effects of immunotherapy are not always understood, it was widely speculated that persistent antitumor effects might be achieved through the generation of antigen-specific T cells. In a recent issue of Blood, Tietze et al. presents an alternative hypothesis, suggesting that - upon the nonspecific stimulation of the immune system - antitumor effects can be mediated by bystander activated memory T cells that are not specific to the tumor itself via their T cell receptors (TCRs).[@R3]

The authors observed that - following cytokine-based immunotherapies such as the administration of agonistic anti-CD40 mAbs and interleukin 2 (IL-2) - CD8^+^ memory T cells expressing granzyme B and possessing elevated lytic capability expand. These cells failed to upregulate CD25 (indicative of TCR engagement) yet highly upregulated the natural killer (NK) cell activating receptor NKG2D. Similar phenotypes were observed using transgenic mice bearing ovalbumin (OVA)-specific TCRs, which therefore were not capable of mounting tumor-specific responses following the same immunotherapeutic regimen. Importantly, OVA-specific T cells elicited by this approach were capable of lysing both OVA-expressing and OVA-negative target cells in vitro, as well as delaying the growth of OVA-negative tumors in vivo. The authors showed that the mechanism by which these nonspecific T cells exert antitumor effects depends - at least partially - on NKG2D, as the blockade of this receptor in vivo resulted in partial abrogation of the anticancer response. Finally, human T cells of a similar phenotype were observed in melanoma patients upon imiquimod treatment, suggesting that this process may be remarkably conserved across species.[@R3] This novel, nonspecific role for CD8^+^ memory T cells in cancer therapy raises many questions.

Presumably, memory T cells have undergone multiple rounds of selection, including (1) central tolerance, (2) peripheral tolerance, and (3) the antigen-driven maturation from a naïve to a memory phenotype. Perhaps, because of this rigorous selection process, these cells may "safely" become activated in a nonspecific (TCR-independent) fashion. Additionally, because these cells are elicited by cytokines yet do not upregulate CD25, they require extremely large amounts of cytokines for survival, perhaps constituting an intrinsic safeguard mechanism. The memory/naïve T cell ratio becomes markedly skewed toward the memory phenotype over the course of a lifespan, due to the facts that the thymus involutes with age[@R4] and that antigen exposure occurs in a near-to-continuous fashion.[@R5] With such a limited ability to generate novel immune responses as we age, this pathway of activation may represent a means to conserve resources and elicit multiple functions (antigen-specific and nonspecific) from a single cell type. Along similar lines, it was recently reported that memory cells are abundant at different sites throughout the body, including the skin.[@R6] Inflammation brought about at these sites by infection, trauma, etc... might generate cytokine-rich environments capable of temporarily inducing local nonspecific memory T-cell activation. Such cells may contribute to immunosurveillance by detecting NKG2D ligand expression on infected and/or transformed cells.

Tietze et al. also suggests that nonspecific CD8^+^ memory T cells may be equipped with inherent advantages over their antigen-specific counterparts, based on their unique phenotype and functional characteristics. For instance, while antigen-nonspecific CD8^+^ memory T cells were found to express NKG2D and low levels of programmed death 1 (PD-1), antigen-specific T cells displayed a NKG2D^-^ and PD-1^high^ phenotype. The description of antigen nonspecific T-cell activation is not novel to cancer immunotherapies, and generally results from potent immunostimulatory interventions. Indeed, similar "bystander" activated cells have been characterized upon viral and bacterial infections[@R7] as well as during autoimmunity.[@R8] Tietze et al. adds to this body of literature with their description of the unique phenotype (NKG2D^pos^ and PD-1^low^) and function (non-MHC restricted cytoxicity) of nonspecific CD8^+^ memory T cells. Tumor cells often downregulate both MHC and tumor antigen expression to avoid recognition by CD8^+^ T cells.[@R9] In this context, nonspecific CD8^+^ T cells that can become activated upon the engagement of NKG2D present an advantage, as this occurs independently of MHC-antigen recognition by the TCR. Furthermore, the differential expression of immunoregulatory molecules such as PD-1 by nonspecific CD8^+^ memory T cells suggests that they may not be susceptible to the same inhibitory pathways as antigen-specific T cells, perhaps constituting an advantage within immunosuppressive tumor microenvironments.[@R10]

From a therapeutic standpoint, the manuscript by Tietze et al. lays the groundwork for how both antigen-specific and nonspecific approaches can be rationally combined to maximize their therapeutic potential. How might this novel role for memory CD8^+^ T cells be exploited for optimizing the efficacy of immunotherapy? Induction of nonspecific bystander CD8^+^ T cells by immunostimulatory therapies might contribute to tumor debulking and hence facilitate the release of tumor antigens. Subsequent vaccination strategies would induce antigen-specific and perhaps prolonged antitumor responses. The activation of the immune system and the release of cytokines at the tumor site by antigen-specific cells may then propagate the survival of nonspecific cells, possibly eliminating the need for further immunostimulatory interventions. This combination could have a 2-fold effect by (i) inducing enhanced, polyclonal specific responses upon the release of otherwise sequestered tumor antigens, and (ii) reducing the side effects that are normally associated with repeated dosing of immunostimulatory therapies (through the generation of antigen-specific cells capable of maintaining nonspecific cells at the tumor and metastatic sites). Importantly, this hypothetical approach may bypass the production of tumor antigen-loss variants that often lead to relapse after immunotherapy. The study by Tietze et al. demonstrates that memory T cells are capable of both extreme specificity as well as nonspecific activities, contingent upon the nature of their stimulation.

![**Figure 1.** Potential synergy between antigen-specific and nonspecific CD8^+^ T cell responses. (1) Immunostimulatory therapies induce αβ memory CD8^+^ T cells to become activated in an antigen-nonspecific fashion, upregulating receptors such as NKG2D. (2) Antigen nonspecific cells can recognize transformed cells via stress ligands, lyse them and hence cause the release of sequestered tumor antigens. (3) Cytokines and chemokines released by nonspecific cells recruit other immune cells including antigen-presenting cells (APCs), which can engulf tumor antigens and hence (4) activate antigen specific CD4^+^ and CD8^+^ T cells. At this stage, vaccination strategies, may aggravate tumor-specific immune responses. (5) Antigen-specific and nonspecific cells are able to attack tumor cells by targeting both tumor antigens and stress ligands, making the arisal of escape variants less likely. (6) Cytokine secretion by antigen-specific cells maintains and continuously recruits antigen nonspecific cells to the tumor site.](onci-1-1208-g1){#F1}
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